Projects

The aim of this programme is to find solutions by building relationships and working together and to enable pharmacists to take an active role in planning solutions.

This project aimed to share the films and photographs created during the SPEAR Digital Diaries project with community members in Sumba and gather feedback and reflections from the community.

In this ‘Photovoice’ project community members in Japapura, Papua, were invited to share their perspectives on leprosy, including about the stigma faced by people living with the disease and their families.

ABACUS phase I (2016-2019) explored antibiotic use and access practices in 6 LMICs and revealed the importance of a context and cultural tailored approach to address responsible antibiotic use in each country. ABACUS phase II (2020-) builds on findings from phase I and aims to investigate the idea of an harmonised physical appearance of antibiotics to facilitate identification from patients and health care professionals.

This study is a randomized, open-label, controlled, group sequential adaptive platform trial, conducted in low-risk patients with Influenza, recruited from outpatient COVID-19/ Acute Respiratory Infection (ARI) clinics or through other approved facilities. Previously healthy patients 18 to 60 years old with early symptomatic Influenza and without co-morbidities are eligible for the study. Enrolled patients are followed up daily for 7 days and then on Day 14. Phone follow-up is conducted on Day 28 and Day 120. This study aims to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this study, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no study drug) and each other. The study currently includes Oseltamivir, Baloxavir, Favipiravir and Molnupiravir in the treatment arms. The key metric to be assessed in this study is the viral clearance rate.

ACT HIV is a parallel-group, randomised (1:1), double-blind, placebo-controlled multi-centre Phase III trial comparing dexamethasone versus placebo for 6–8 weeks in addition to standard anti-tuberculosis and antiretroviral treatment.

There is a global need and opportunity to implement and scale effective early warning systems (EWS) to rapidly detect future outbreaks of infectious diseases with epidemic or pandemic potential. A crucial first step in this process is establishing a strong knowledge base to build upon.

Analyses of correlates of SARS-CoV-2 infection or mortality have usually assessed individual predictors. This study aimed to determine if patterns of combined predictors may better identify risk of infection and mortality.

This project aims to compare the impact of a package of interventions on clinical outcomes and antibiotic prescriptions.